Q-omics provides the consensus-scored MIR562 profile across patient tissues and cancer cell-line models. MIR562 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR562 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, MIR562 RNA expression shows 7,845 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight ACC, KIRC, and LAML as cancer lineages where MIR562 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR562 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR562 survival associations across molecular data types. MIR562 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR562 RNA expression–survival associations across cancer types. High MIR562 expression shows unfavorable associations in ACC, UCEC, KIRP, PAAD and STAD, but favorable associations in LAML. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR562 RNA expression.
This table summarizes MIR562 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR562. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR562 shows higher tumor expression in KIRC, BRCA and STAD. The KIRC box plot shows higher MIR562 RNA expression in tumor versus normal tissue (log2 FC = +0.068, t-test p = .026).
This table shows molecular features associated with MIR562 in patient tissues and cancer cell lines. In patient samples, MIR562 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
